Novo Nordisk's Wegovy earns B+ from US nonprofit research organization
The Institute for Clinical and Economic Review has reviewed the Danish firm’s obesity drug next to other treatments, concluding it is better overall but more expensive than typical cost-effectiveness thresholds.
by marketwire, translated by daniel pedersen
Novo Nordisk’s Wegovy is a ”step forward” when it comes to increasing the weight loss of people with obesity, according to US-based nonprofit research organization the Institute for Clinical and Economic Review, or ICER, which has assessed the comparative clinical effectiveness of several obesity treatments.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Wegovy celebrates first birthday with subdued cheers
For subscribers
.jpg)
.jpg&w=384&q=75)
